Medpace Acquires Pharma Brains AG
Cincinnati, OH-November 2, 2009
Medpace has entered into a purchase agreement to acquire Pharma Brains AG, an oncology focused CRO based in Basel, Switzerland.
Pharma Brains is led by Dr. Marc Salzberg, President and CEO, a research professional with extensive experience in oncology Phase I-IV studies as well as drug development and regulatory affairs.
"I am pleased to have Dr. Salzberg joining the group as an integral leader beginning with the integration and going forward as the VP of Oncology, Europe and General Manager, Switzerland," said Dr. August Troendle, President and CEO, Medpace. "Marc Salzberg is a distinguished professional in European drug development and brings 17 years of industry and leadership experience to Medpace."
The integration of Pharma Brains operations will begin immediately with the intent of completing the merger by the end of 2009.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
